UNSPSC 51431705: Clentiazem

This classification denotes a calcium channel blocker with the molecular formula C22H25CLN2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 40DK034DRC chemically known as 1,5-benzothiazepin-4(5h)-one, 3-(acetyloxy)-8-chloro-5-(2-(dimethylamino)ethyl)-2,3-dihydro-2-(4-methoxyphenyl)-, (2s-cis)- but generally known as clentiazem, which bears US NIH Compound Identifier 57026. European Medicines Agency schedules Clentiazem in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06653MIG.

UNSPSC 51431705 Clentiazem (Commodity) covers emergency and acute-care pharmaceuticals supplied to state and local public health and safety agencies, as evidenced by recent solicitations for emergency medications and therapeutic pharmacy programs. State and local governments procure these medications primarily through fire rescue departments, health service agencies, and multi-state cooperative purchasing alliances for use in emergency medical services and hospital settings. The scope includes individual medication line items supplied with firm pricing, specified expiration-date requirements, and delivery guarantees, as well as participation in broader pharmacy benefit programs that source multiple pharmaceutical products through authorized wholesalers. Issuing bodies include municipal fire and rescue departments, state health and human services commissions, and multi-state cooperative purchasing organizations serving hospitals and public health facilities across multiple jurisdictions.

Recent activity spans Florida, Texas, and Minnesota, with representative solicitations including the City of Tampa's Purchasing Department IFB No. 26P00188 for Advanced Life Support Medications (response due April 8, 2026, estimated value $40,000) supplying diltiazem vials, epinephrine, labetalol, and adenosine to Tampa Fire Rescue; the Texas Health and Human Services Commission RFI No. HHS0017013 exploring direct-to-manufacturer prescription programs (posted April 3, 2026); and the Minnesota Multistate Cooperative Purchasing Alliance RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products with an effective date of July 1, 2026. The Tampa solicitation carries a Small Local Business Enterprise sheltered-market designation with a 5 percent bid discount, and requires Safety Data Sheets, WCAG 2.2 accessibility documentation, and OSHA Hazard Communication compliance. The MMCAP procurement requires vendors to maintain relationships with AmerisourceBergen Drug Corporation, Cardinal Health, or Morris & Dickson Co. as authorized wholesalers and to meet cGMP and Drug Supply Chain Security Act certifications.